BridgeBio(BBIO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing re ...